DIRS.INFO The most relevant business & tech news

☆ Promise of Eli Lilly's weight-loss drug for sleep apnea adds another reason to own the stock
▼ + stars: | 2024-04-17 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly said it plans to ask U.S. regulators to expand Zepbound's label to include obstructive sleep apnea, or OSA, later this year. Shares of Eli Lilly have ridden the GLP-1 craze to new heights over the past few years. The current standard of care for obstructive sleep apnea is positive airway pressure, or PAP, machines, which help keep patients' airways open while they sleep. Analysts projected obstructive sleep apnea revenue of $3 billion. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Persons: Eli Lilly, Zepbound, it's, Mounjaro, Lilly, Jim Cramer, Jim, Eli Lilly YTD, Morgan Stanley, Jim Cramer's, Eli Lilly’s, Brendan Mcdermid Organizations: Novo Nordisk, GLP, OSA, Mayo, U.S, CNBC, Cleveland Clinic, National Council, Aging, Deutsche Bank, American Diabetes Association, Novo Nordisk's Ozempic, Bank of America Locations: U.S, Novo, New York City

☆ Eli Lilly's top-selling drug last year is softening. But it may not matter for the stock
▼ + stars: | 2024-04-12 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Sales of some Eli Lilly drugs — including its best-selling product last year — appear to be softening, according to Wall Street analysts. JPMorgan flagged similar trends for Trulicity, which led all Lilly drugs with $7.13 billion in sales for all of 2023. The thesis is predicated on Eli Lilly growing faster than the broader pharmaceutical industry for years to come. Over the past three years, shares of Eli Lilly have soared nearly 300%, compared with a 24% gain for the S & P 500 . A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.

Persons: Eli Lilly, Wells, Lilly, Mounjaro, Jim Cramer, tirzepatide, Zepbound, Eli Lilly's, Novo, Wegovy, drugmaker, Jim Cramer's, Jim, Eli Lilly Pharmaceutical, George Frey Organizations: Wall Street, JPMorgan, Club, Novo Nordisk, Novo, BMO Capital Markets, Drug Administration, FDA, The Club, CNBC Locations: Wells Fargo, Trulicity, Tirzepatide, Danish, Lilly, Provo , Utah

☆ Viking Therapeutics' weight loss drug showed faster results in clinical trials than Ozempic or Wegovy. Here's how it works.
▼ + stars: | 2024-02-28 | by ( ) www.businessinsider.com time to read: +3 min

Biotech company Viking Therapeutics saw stock prices double after a report on weight loss drug VK2735. The new drug could lead to even more weight loss at a faster pace than Ozempic or Mounjaro. Viking Therapeutics, a small California-based biotech company, shared the topline results from a mid-stage trial of its drug VK2735 on February 27. AdvertisementHowever, the early results of clinical trials suggest it could be on par to offer even more weight loss in less time than its competitors. How Viking Therapeutics' weight-loss drug worksVK2735 mimics two hormones that affect weight control.

Persons: —, Eli Lilly, GIP, VK2735 Organizations: Biotech, Viking Therapeutics, Service, Novo Nordisk, Washington Post, Therapeutics, Viking Locations: California

☆ Eli Lilly's rally on blowout Mounjaro sales signals a new leg higher for the stock
▼ + stars: | 2023-11-02 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

LLY YTD mountain Eli Lilly's year-to-date stock performance. Investors are understandably cheering the results, sending Eli Lilly shares higher by more than 4%. "Eli Lilly today is beginning its next leg of going up," Jim Cramer said during Thursday's Morning Meeting . The most important line item was Mounjaro sales, which cleared Wall Street's high bar. Excluding that divestiture and the $387 million in Covid antibody sales in the year-ago quarter, Eli Lilly's sales grew 24% on an annual basis — a highly respectable figure.

Persons: Eli Lilly, LLY, Mounjaro, it's, Eli Lilly's, Jim Cramer, Jim, It's, Novo's, Lilly, We're, Dave Ricks, Ricks, Trulicity, Anat Ashkenazi, Lilly —, Ashkenazi, Jim Cramer's, David Ricks, Eli Lilly Scott Mlyn Organizations: Drug Administration, FDA, Novo Nordisk, CNBC, Management, Dice Therapeutics, Therapeutics Locations: North, Concord , North Carolina, U.S, Indianapolis

☆ Monthly Meeting Q&A with Jim Cramer on everything from tech to health care to industrials
▼ + stars: | 2023-10-12 | by ( Paulina Likos | ) www.cnbc.com time to read: +13 min

(Todd) Jim Cramer: I believe that the rally in oil was a short squeeze that is now over. (John) Jim Cramer: FTC chair Lina Khan does not have a strong antitrust case against Amazon (AMZN) – her arguments don't make sense. (Norman) Jim Cramer: We like to have something related to the housing cycle that could make money. (James) Jim Cramer: This is more of an art, not a science. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer's, Jeff Marks, Jim Cramer, It's, Todd, Joe Biden, Tom Jorden, Donald, John, it's, Zev Fima, I've, Peter, Marc Benioff, Lina Khan, Khan, David, Rich Galanti, Eli Lilly, LLY, we've, Lilly, clobbered, Mounjaro, Stanley Black, Decker, that's, James, Michael Steinhardt, Rhonda, Vimal Kapur, Darius Adamczyk, Jim Organizations: Investing Club, Federal Reserve, Nvidia, Fed, Apple, Shark, ESPN, Our, Nasdaq, Amazon, Costco, Diabetes, Procter & Gamble, Honeywell, Electric, GE, Raytheon Technologies, CNBC Locations: Russia, China

☆ Why investors should buy these fixer-upper names, while sticking with 3 that are set to soar
▼ + stars: | 2023-10-11 | by ( Morgan Chittum | ) www.cnbc.com time to read: +6 min

Oracle Oracle (ORCL) stock has been sliding for some time, with shares down 14% over the past month, even as the stock has climbed more than 33% this year. He added that this is a great level at which to buy Oracle stock. And here are three Club names that need no work, and are well-positioned to soar: Caterpillar Caterpillar (CAT) has weathered the market's volatility well. TJX Companies This is TJX Companies ' (TJX) time to shine, as the off-price retailer has the best business model to capture the spending of a cash-strapped consumer. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer, Walt Disney, Jim, Disney's, Nelson Peltz, Laxman Narasimhan, There's, Larry, Ellison, it's, we're, TJX, Eli Lilly Eli Lilly, Mounjaro —, Jim Cramer's, Angela Weiss Organizations: Nasdaq, Treasury, Club, Disney, Walt, ESPN, Comcast, Hulu, CNBC, Starbucks, U.S, Oracle Oracle, Oracle, Caterpillar Caterpillar, Caterpillar, Traders, New York Stock Exchange, AFP, Getty Locations: NBCUniversal, China, U.S, Maxx, New York City

☆ These are the top 4 Club stocks — and the bottom 4 — during the third quarter
▼ + stars: | 2023-09-30 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +11 min

Here's a look at the top four and bottom four Club stocks in the third quarter as Wall Street gears up for the first trading day of the fourth quarter on Monday. The winners LLY mountain 2023-06-30 Eli Lilly's stock performance in the third quarter. CAT mountain 2023-06-30 Caterpillar's stock performance in the third quarter. F mountain 2023-06-30 Ford Motor's stock performance since the end of the second quarter. In the first few weeks of the quarter, shares of the medical equipment giant actually edged higher, but its fortunes would turn significantly.

Persons: —, Eli Lilly, Eli Lilly's, Lilly, Wegovy —, Microsoft's, Locker, Mary, Jim Cramer, Dillon, Estee Lauder, we're, Fabrizio Freda, Stellantis, Ford, Jim, we've, there's, Foot Locker, GE Healthcare's, Jim Cramer's, Frederick Florin Organizations: Federal Reserve, Dow Jones, Nasdaq, Dow, Novo Nordisk, Investors, Caterpillar, Natural Resources, West Texas, Google, Microsoft, FL, Ford, United Auto Workers, UAW, General Motors, Detroit, GM, GE, GE Healthcare, CNBC, AFP, Getty Locations: U.S, WTI, Asia, Illinois, Estee Lauder, GOOGL, Fegersheim, France

☆ The N.Y.C. Neighborhood That’s Getting Even Thinner on Ozempic
▼ + stars: | 2023-08-26 | by ( Joseph Goldstein | More About Joseph Goldstein | ) www.nytimes.com time to read: +1 min

The Upper East Side is one of the city’s wealthiest and healthiest neighborhoods. It has one of the highest life expectancies, and among the lowest rates of diabetes and obesity in New York City. Now the neighborhood’s residents are getting even thinner. That was the highest rate in New York City. “The running game show of the 10021 ZIP code is guessing who is on Vitamin O” — that is, Ozempic, said the writer, actress and Upper East Side native, Jill Kargman, referring to what has long been the city’s toniest ZIP code, covering much of the East 70s.

Persons: Jill Kargman Organizations: Gramercy, Trilliant Health Locations: New York City, Manhattan, Brooklyn

☆ Promise around Eli Lilly's expected obesity drug, great earnings adds some $60 billion in market cap
▼ + stars: | 2023-08-08 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +9 min

(When excluding one-time divestment contributions and last year's Covid antibody revenue, Lilly's sales rose 22% on an annual basis.) Eli Lilly shares soared more than 16% to a new all-time high during Tuesday's session. LLY YTD mountain Eli Lilly's stock performance so far in 2023. Eli Lilly now expects adjusted earnings per share between $9.70 and $9.90, up significantly from the old guidance between $8.65 and $8.85. For its part, Eli Lilly is also studying Mounjaro's impact on other health outcomes including cardiovascular events.

Persons: Eli Lilly, Mounjaro, —, Jim Cramer's, Jim, Lilly's, Cheplapharm —, Lilly, Anat Ashkenazi, Ashkenazi, Eli Lilly's, Lilly Diabetes, Michael Mason, Mason, Verzenio, Trulicity, we've, David Ricks, Jim Cramer, Cristina Arias Organizations: Novo Nordisk, U.S, Amphastar Pharmaceuticals, Management, CNBC, Company, Pharmaceutical Locations: Indianapolis, North Carolina, U.S, Trulicity, Danish, Novo, Alcobendas, Madrid, Spain

☆ Medicare is barred from paying for weight-loss drugs like Wegovy. Lawmakers just took the first step to change that.
▼ + stars: | 2023-07-20 | by ( ) www.businessinsider.com time to read: +5 min

Medicare is barred under a 2003 law from paying for weight-loss medications like Wegovy. Lawmakers on Thursday reintroduced a bill that would expand Medicare coverage to the drugs. A major roadblock has long stood in the way of older Americans getting treatments for obesity: Medicare. But US lawmakers on Thursday took steps to broaden access to weight-loss treatment for seniors. Medicare coverage might prod other health insurers to pay for weight-loss medications, as private health plans tend to follow Medicare's lead.

Persons: Democratic Sen, Tom Carper, Carper, Republican Sen, Bill Cassidy, Raul Ruiz, Brad Wenstrup, Eli Lilly's Mounjaro, Wegovy, Eli Lilly, clamor, Chris Gallagher Organizations: Medicare, Democratic, Republican, California Democrat, Lawmakers, Nordisk's Wegovy, Vanderbilt University, Novo Nordisk, Wall Street Journal, Obesity, Coalition Locations: California, Ohio

☆ Inside your company's struggle over whether to pay for hot, new weight-loss drugs
▼ + stars: | 2023-06-20 | by ( ) www.businessinsider.com time to read: +10 min

Americans are clamoring for new weight-loss drugs, but companies aren't rushing to pay for them. At most, half of US employers help pay for weight-loss drugs for their workers, according to several estimates. "The drug companies, providers, and patient groups are insisting that weight loss will improve health and therefore offset these massive costs. Known as GLP-1 agonists, the drugs — Wegovy and Ozempic from Novo Nordisk and Eli Lilly's Mounjaro — mimic a gut hormone known as glucagon-like peptide 1, helping to suppress people's appetites and slow their digestion. Brent Eberle, the chief pharmacy officer at Navitus, said very few of the employers that worked with his pharmacy-benefit manager paid for weight-loss drugs.

Persons: that's, They're, AJ Loiacono, Li Ran, James Gelfand, Eli Lilly's, Ozempic, drugmakers, Brent Eberle, Navitus, Eberle, it's, Pat Gleason, Gleason, Wegovy, Eli Lilly, Lilly, Florian Gaertner, Loiacono Organizations: Morning, Novo Nordisk, Getty, Workers, Drugmakers, Therapeutics, Blue, Mayo Clinic, and Drug Administration, Capital Locations: Novo, Xinhua

Eli Lilly also is expected to present data on another weight-loss drug called orforglipron, which patients take orally instead of through an injection. Retatrutide, Mounjaro and weight-loss drug Wegovy, produced by rival Novo Nordisk (NVO), are all injectable. But if the data were to fall short of expectations, the analysts don't foresee much downside to J & J shares. However, with JNJ-2113, Morgan Stanley noted that J & J management has touted its efficacy profile "without the baggage of a JAK label." J & J has consistently denied those accusations.

Persons: Eli Lilly, Johnson, Morgan Stanley —, Eli Lilly Eli Lilly, Morgan Stanley, Eli Lilly's Mounjaro, Mounjaro, Lilly's, retatrutide, hasn't, haven't, Jim Cramer's, Jim Cramer, Jim, AJ Mast Organizations: American Diabetes Association, Novo Nordisk, U.S . Food, Drug Administration, Pfizer, Novo Nordisk's, Johnson, American Academy of Dermatology, topline, J's, LTL Management, CNBC, Bloomberg, Getty, & ' $ Locations: U.S, Novo, Indianapolis , Indiana

☆ What Ozempic and Addiction Drugs Reveal About Desire - The New York Times
▼ + stars: | 2023-06-04 | by ( Maia Szalavitz | ) www.nytimes.com time to read: +1 min

Mary Boyer, a 41-year-old tech worker, started taking the drug Mounjaro last October to treat obesity. Mounjaro — like the better-known Ozempic — is one of a new class of diabetes and obesity drugs that work differently from earlier medications in ways that are not yet fully understood. Unlike stimulants, which can be addictive, these drugs may fight addictions and not just those related to food. Discovering how the new weight loss medications alter appetite and the compulsive behavior that can be associated with it could offer new insight into the nature of pleasure and addictions. When drugs can significantly ease weight loss or addiction recovery, it’s hard to argue that the problem is moral rather than medical.

Persons: Mary Boyer, “ I’m, ”, “, ’ ”, Mounjaro

☆ We're making five price target changes and one rating upgrade after a crazy week of earnings
▼ + stars: | 2023-05-07 | by ( Jeff Marks | ) www.cnbc.com time to read: +6 min

AAPL YTD mountain Apple YTD performance Apple (AAPL): We're raising our price target to $185 per share from $175 in response to the strong quarter Thursday evening. LLY YTD mountain Eli Lilly YTD performance Eli Lilly (LLY): We're increasing our price target on Eli Lilly again, this time to $460 per share from $430. Our new price target is in reaction to the positive Alzheimer's drug trial data that was much better than what we expected. HAL YTD mountain Halliburton YTD performance Halliburton (HAL): We are lowering our price target on this North American-focused oil services giant to $40 per share from $48. SBUX YTD mountain Starbucks YTD performance Starbucks (SBUX): We're bumping up our price target to $125 per share from $120 and upgrading our rating to a 1 following the stock's pullback in reaction to the recent earnings result .

☆ Here's why you don't bring a trader knife to a bull gunfight — and other lessons for navigating this new market
▼ + stars: | 2023-02-04 | by ( Jim Cramer | ) www.cnbc.com time to read: +6 min

What matters in a real bull market, though, is the company and the sector it's in, not the S & P 500 . So, the first lesson is to understand that in a bull market the buyer gets the benefit of the doubt, not the seller. Secondly, in a bull market you have to fight the temptation to trade down. So, again, know that in a bull market the sellers better have a lot of conviction or else they will lose the opportunity to make money. It's our job to keep you from doing so by helping you to navigate this bull market that started in October 2022 — a bull market that almost no one seems to recognize except us.

☆ I prescribe the popular weight-loss drug semaglutide to my patients. I hesitate to call it a magic bullet.
▼ + stars: | 2023-01-18 | by ( Hannah Moseley | ) www.businessinsider.com time to read: +7 min

Dr. Paul Kolodzik has been prescribing semaglutide to his diabetic patients since 2017. The one regret he hears from patients on the drug is they can't enjoy food as much. Before that, I was an emergency physician for about 25 years, caring for patients with strokes, heart attacks, and diabetic emergencies. I started prescribing semaglutide under the label Ozempic to my diabetic patients in 2017Novo Nordisk, a global pharmaceutical company, developed Ozempic as a medication for diabetics to control their blood sugar. So, physicians started prescribing some patients who weren't diabetic Ozempic off-label since Ozempic is not approved for weight loss — even though it's the same generic medicine.

☆ Credit Suisse touts drug stocks as a top place to be. These are our 2 favorites
▼ + stars: | 2022-11-18 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Like the Club, Credit Suisse holds a positive view on Mounjaro — the company's diabetes drug that's shown immense promise as an obesity treatment, too — and Lilly's latest experimental Alzheimer's drug ahead of a pivotal data release expected next year. However, we differ on J & J, which will soon break itself up. The remaining J & J will be its current pharmaceutical and medical technologies divisions. Credit Suisse rates J & J as neutral with a $170 price target, which is nearly 4% below where the stock closed Thursday. A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.

☆ After this week's big market rally, here's a rapid-fire update on all 32 stocks in our portfolio
▼ + stars: | 2022-11-11 | by ( Jeff Marks | ) www.cnbc.com time to read: +6 min

Cisco Systems (CSCO): It reports next week and we think it should deliver a decent quarter as it converts its backlog into revenue. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade.

☆ Eli Lilly's guidance cut is about the strong dollar, not weakening fundamentals, CEO says
▼ + stars: | 2022-11-01 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Eli Lilly — which generates about 40% of its sales overseas — largely attributed the guidance cut to the strong U.S. dollar. With three quarters already reported, Eli Lilly now expects full-year sales to range between $28.5 billion to $29 billion and adjusted per-share earnings between $7.70 to $7.85. New diabetes drug off to great start One of our biggest reasons for liking Eli Lilly is the company's new type 2 diabetes drug that's also shown promise as an obesity treatment . The drug is similar to one that Eli Lilly is working to treat the most common form of dementia. David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC

Search resuls for: "Mounjaro —"

19 mentions found